Neuregulin-4 - Avexegen Therapeutics
Alternative Names: NRG-4 - Avexegen TherapeuticsLatest Information Update: 28 Nov 2022
At a glance
- Originator Avexegen Therapeutics
- Class Anti-inflammatories; Peptides
- Mechanism of Action Neuregulin replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Necrotising enterocolitis
- No development reported Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
Most Recent Events
- 28 Nov 2022 No recent reports of development identified for preclinical development in Crohn's-disease in USA (PO)
- 28 Nov 2022 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in USA (PO)
- 28 Nov 2022 No recent reports of development identified for preclinical development in Ulcerative-colitis in USA (PO)